[
  {
    "ts": null,
    "headline": "Why AbbVie Stock Flew Higher on Friday",
    "summary": "A solid quarterly earnings report reverberated though the pundit community that day.",
    "url": "https://finnhub.io/api/news?id=802cdc49800321c9b2c1833427bd238b661c0f48c62363b629a022bca7e950a9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754085720,
      "headline": "Why AbbVie Stock Flew Higher on Friday",
      "id": 136183233,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "A solid quarterly earnings report reverberated though the pundit community that day.",
      "url": "https://finnhub.io/api/news?id=802cdc49800321c9b2c1833427bd238b661c0f48c62363b629a022bca7e950a9"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie (ABBV) Reports Increased Sales But Lower Net Income For Q2 2025",
    "summary": "AbbVie (ABBV) recently revealed mixed financial Q2 2025 results with increased sales but a drop in net income and EPS, alongside strategic pursuits such as potential acquisitions and new product developments. Despite these developments, AbbVie's share price remained flat over the past month. This modest movement could reflect broader market trends influenced by macroeconomic concerns such as Trump's tariff announcements and a weaker-than-expected jobs report, which led to broader market...",
    "url": "https://finnhub.io/api/news?id=19f5eaf07e3790a69ea9c50fb1262af0a43da65be4966590eb5f1f80e6c715c9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754071819,
      "headline": "AbbVie (ABBV) Reports Increased Sales But Lower Net Income For Q2 2025",
      "id": 136183234,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie (ABBV) recently revealed mixed financial Q2 2025 results with increased sales but a drop in net income and EPS, alongside strategic pursuits such as potential acquisitions and new product developments. Despite these developments, AbbVie's share price remained flat over the past month. This modest movement could reflect broader market trends influenced by macroeconomic concerns such as Trump's tariff announcements and a weaker-than-expected jobs report, which led to broader market...",
      "url": "https://finnhub.io/api/news?id=19f5eaf07e3790a69ea9c50fb1262af0a43da65be4966590eb5f1f80e6c715c9"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Soars On Skyrizi And Rinvoq Strength, Outpacing Humira Erosion",
    "summary": "On Thursday, AbbVie Inc. (NYSE:ABBV) reported second-quarter 2025 sales of $15.42 billion on Thursday, beating the consensus of $14.98 billion. Sales increased 6.6% on a reported basis or 6.5% on an operational basis. The company reported adjusted earnings of $2.97, up 12.1% year over year and missing the consensus of $3.23. AbbVie raised its fiscal 2025 adjusted earnings from $11.67-$11.87 per share to $11.88-$12.08 compared to the analysts’ estimate of $12.24. Also Read: Trump Issues 60 Day Ul",
    "url": "https://finnhub.io/api/news?id=916f1f9fbc3b449afed139aa7b1cf42c121a4d6a10596afc3e292a227cd8bebc",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754071490,
      "headline": "AbbVie Soars On Skyrizi And Rinvoq Strength, Outpacing Humira Erosion",
      "id": 136183235,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "On Thursday, AbbVie Inc. (NYSE:ABBV) reported second-quarter 2025 sales of $15.42 billion on Thursday, beating the consensus of $14.98 billion. Sales increased 6.6% on a reported basis or 6.5% on an operational basis. The company reported adjusted earnings of $2.97, up 12.1% year over year and missing the consensus of $3.23. AbbVie raised its fiscal 2025 adjusted earnings from $11.67-$11.87 per share to $11.88-$12.08 compared to the analysts’ estimate of $12.24. Also Read: Trump Issues 60 Day Ul",
      "url": "https://finnhub.io/api/news?id=916f1f9fbc3b449afed139aa7b1cf42c121a4d6a10596afc3e292a227cd8bebc"
    }
  },
  {
    "ts": null,
    "headline": "Why AbbVie (ABBV) Stock Is Up Today",
    "summary": "Shares of pharmaceutical company AbbVie (NYSE:ABBV) jumped 3.7% in the afternoon session after the company posted strong second-quarter earnings that beat expectations and raised its full-year financial forecast. The pharmaceutical giant disclosed adjusted earnings of $2.97 per share and revenues of $15.42 billion, both numbers surpassing analyst estimates. This performance was driven by robust sales from its immunology drugs, Rinvoq and Skyrizi, which successfully offset lower sales from the co",
    "url": "https://finnhub.io/api/news?id=91782be822b7184c9e8a364455bcf8f0dfb20fdd2817ac224b2760f78469a1e0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754065545,
      "headline": "Why AbbVie (ABBV) Stock Is Up Today",
      "id": 136183236,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Shares of pharmaceutical company AbbVie (NYSE:ABBV) jumped 3.7% in the afternoon session after the company posted strong second-quarter earnings that beat expectations and raised its full-year financial forecast. The pharmaceutical giant disclosed adjusted earnings of $2.97 per share and revenues of $15.42 billion, both numbers surpassing analyst estimates. This performance was driven by robust sales from its immunology drugs, Rinvoq and Skyrizi, which successfully offset lower sales from the co",
      "url": "https://finnhub.io/api/news?id=91782be822b7184c9e8a364455bcf8f0dfb20fdd2817ac224b2760f78469a1e0"
    }
  },
  {
    "ts": null,
    "headline": "3 Dividend Healthcare Stocks to Buy Hand Over Fist Before They Double",
    "summary": "These pharmaceutical giants are well worth a second look.",
    "url": "https://finnhub.io/api/news?id=6676740bb5f45546f4ecd3c7c9c472208a138515f0e883926f0f512ffffb1a95",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754056800,
      "headline": "3 Dividend Healthcare Stocks to Buy Hand Over Fist Before They Double",
      "id": 136165216,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "These pharmaceutical giants are well worth a second look.",
      "url": "https://finnhub.io/api/news?id=6676740bb5f45546f4ecd3c7c9c472208a138515f0e883926f0f512ffffb1a95"
    }
  },
  {
    "ts": null,
    "headline": "Fibromyalgia Market Analysis Report 2025-2035 | Key Players Drive Competition in Expanding Treatment Options",
    "summary": "Fibromyalgia, a complex chronic pain disorder marked by widespread pain, fatigue, and cognitive issues, is witnessing evolving treatment advancements. The global market is experiencing growth through novel drugs targeting central sensitization, increased use of digital health tools, and personalized medicine. Enhanced diagnostic criteria are aiding improved disease management, although challenges like underdiagnosis and limited treatment efficacy persist. Key areas like North America and Europe",
    "url": "https://finnhub.io/api/news?id=e13ac23a2d216dd7614073e2f624b836e3acc1520eed340025bbc9e600885109",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754038800,
      "headline": "Fibromyalgia Market Analysis Report 2025-2035 | Key Players Drive Competition in Expanding Treatment Options",
      "id": 136165282,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Fibromyalgia, a complex chronic pain disorder marked by widespread pain, fatigue, and cognitive issues, is witnessing evolving treatment advancements. The global market is experiencing growth through novel drugs targeting central sensitization, increased use of digital health tools, and personalized medicine. Enhanced diagnostic criteria are aiding improved disease management, although challenges like underdiagnosis and limited treatment efficacy persist. Key areas like North America and Europe",
      "url": "https://finnhub.io/api/news?id=e13ac23a2d216dd7614073e2f624b836e3acc1520eed340025bbc9e600885109"
    }
  },
  {
    "ts": null,
    "headline": "Tenosynovitis Market Research Report 2025-2035 | Rising Demand for Tenosynovitis Treatment Amid Increasing Rheumatoid Arthritis Cases",
    "summary": "Embracing Innovation in Tenosynovitis Treatment: The global Tenosynovitis market is advancing rapidly, driven by the rising prevalence of inflammatory diseases like rheumatoid arthritis. As aging populations increase, demand grows for effective treatments to manage this tendon sheath inflammation. Biologic and targeted therapies, including TNF and IL-6 inhibitors, are at the forefront, alongside non-invasive options like PRP therapy. Leading companies such as Pfizer and AbbVie are fueling innova",
    "url": "https://finnhub.io/api/news?id=e52353e274c9e47c5cb25f66391671b7e07291da485e59ee4d235401e742eb2e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754037000,
      "headline": "Tenosynovitis Market Research Report 2025-2035 | Rising Demand for Tenosynovitis Treatment Amid Increasing Rheumatoid Arthritis Cases",
      "id": 136165283,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Embracing Innovation in Tenosynovitis Treatment: The global Tenosynovitis market is advancing rapidly, driven by the rising prevalence of inflammatory diseases like rheumatoid arthritis. As aging populations increase, demand grows for effective treatments to manage this tendon sheath inflammation. Biologic and targeted therapies, including TNF and IL-6 inhibitors, are at the forefront, alongside non-invasive options like PRP therapy. Leading companies such as Pfizer and AbbVie are fueling innova",
      "url": "https://finnhub.io/api/news?id=e52353e274c9e47c5cb25f66391671b7e07291da485e59ee4d235401e742eb2e"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Inc (ABBV) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and Raised Guidance ...",
    "summary": "AbbVie Inc (ABBV) surpasses expectations with robust sales from Skyrizi and Rinvoq, while navigating Humira declines and aesthetics challenges.",
    "url": "https://finnhub.io/api/news?id=1152339f31cbf33c28218084124001b4f689f0448986f5a9b4d91a92db6521a8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754032845,
      "headline": "AbbVie Inc (ABBV) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and Raised Guidance ...",
      "id": 136165284,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie Inc (ABBV) surpasses expectations with robust sales from Skyrizi and Rinvoq, while navigating Humira declines and aesthetics challenges.",
      "url": "https://finnhub.io/api/news?id=1152339f31cbf33c28218084124001b4f689f0448986f5a9b4d91a92db6521a8"
    }
  },
  {
    "ts": null,
    "headline": "Trump doubles down on Most Favored Nation plan to target drug prices",
    "summary": "Major pharma manufacturers have a 29 September deadline to adjust their drug prices relative to other developed countries.",
    "url": "https://finnhub.io/api/news?id=caa6f76ac187f7e7b18c00b896f616e50ea68bcbacfbe1ae0a2120c6d6cb861c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754008407,
      "headline": "Trump doubles down on Most Favored Nation plan to target drug prices",
      "id": 136160868,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Major pharma manufacturers have a 29 September deadline to adjust their drug prices relative to other developed countries.",
      "url": "https://finnhub.io/api/news?id=caa6f76ac187f7e7b18c00b896f616e50ea68bcbacfbe1ae0a2120c6d6cb861c"
    }
  }
]